Kromatid Inc., of Denver, said it completed a series A financing round with Denver-based First Capital Ventures, with the amount cited in an SEC filing as $1.85 million. The company said the funding will support development of its directional genomic hybridization, or DGH, platform to provide the gene editing field with tools for single cell structural genomic analysis to support therapeutic development programs.